Aton Ra Partners Nurix Therapeutics, Inc. Transaction History
Aton Ra Partners
- $50.1 Million
- Q4 2023
A detailed history of Aton Ra Partners transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Aton Ra Partners holds 21,102 shares of NRIX stock, worth $207,854. This represents 0.43% of its overall portfolio holdings.
Number of Shares
21,102
Previous 24,227
12.9%
Holding current value
$207,854
Previous $190,000
14.21%
% of portfolio
0.43%
Previous 0.4%
Shares
11 transactions
Others Institutions Holding NRIX
# of Institutions
183Shares Held
67MCall Options Held
318KPut Options Held
42.4K-
Black Rock Inc. New York, NY6.82MShares$67.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.35MShares$42.8 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.19MShares$41.3 Million6.18% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$38.2 Million0.81% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.01MShares$29.6 Million0.01% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $464M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...